Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the transaction, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at $17,208,443.70. The trade was a 3.74 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total transaction of $739,920.00.
• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $106.80, for a total value of $854,400.00.

Vaxcyte Stock Performance

Shares of PCVX traded up $1.56 during mid-day trading on Friday, reaching $84.86. The company had a trading volume of 786,150 shares, compared to its average volume of 771,175. Vaxcyte, Inc. has a 52 week low of $53.83 and a 52 week high of $121.06. The company has a market capitalization of $10.58 billion, a price-to-earnings ratio of -18.45 and a beta of 0.94. The firm has a 50-day moving average price of $93.19 and a 200 day moving average price of $92.84.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the prior year, the company earned ($0.91) EPS. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Institutional Trading of Vaxcyte

A number of institutional investors have recently made changes to their positions in PCVX. Riverview Trust Co purchased a new stake in Vaxcyte during the 3rd quarter valued at $27,000. Blue Trust Inc. increased its position in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after acquiring an additional 93 shares during the last quarter. Meeder Asset Management Inc. lifted its holdings in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares during the period. Nomura Asset Management Co. Ltd. purchased a new position in Vaxcyte in the third quarter worth about $92,000. Finally, Quest Partners LLC bought a new stake in shares of Vaxcyte during the 2nd quarter valued at about $70,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Mizuho increased their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Needham & Company LLC reissued a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and a consensus price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.